All pages
Jump to navigation
Jump to search
- 5-FU
- 5-fluorouracil
- 5FU
- ABT-199 (GDC-0199)
- AG-120
- AG-221
- AHUS
- AIHA
- ALCL
- ALL
- AMG 330
- AMG 386
- ARN-509
- ATLL
- AZD5363
- Abarelix (Plenaxis)
- Abciximab (ReoPro)
- Abemaciclib (LY2835219)
- Abemaciclib (Verzenio)
- Abexinostat (PCI-24781)
- Abiraterone
- Abiraterone (Zytiga)
- Abraxane
- Academic Medicine exhibit
- Academic Medicine standard narrative
- Academic Medicine wiki-based narrative
- Acalabrutinib (ACP-196)
- Acalabrutinib (Calquence)
- Acetaminophen (Tylenol)
- Acetazolamide (Diamox)
- Aclarubicin (Aclacinomycin)
- Aclarubicin (Aclacinon)
- Acquired coagulopathy
- Actinium-225 (225Ac)-Lintuzumab (Actimab-A)
- Actinium Ac 225 lintuzumab (Actimab-A)
- Acute lymphocytic leukemia
- Acute myeloblastic leukemia
- Acute myelogenous leukemia
- Acute myeloid leukaemia
- Acute myeloid leukaemia, FLT3-positive
- Acute myeloid leukaemia, IDH-mutated
- Acute myeloid leukemia
- Acute myeloid leukemia, FLT3-positive
- Acute myeloid leukemia, IDH-mutated
- Acute myeloid leukemia, NPM1-mutated
- Acute myeloid leukemia, pediatric
- Acute myeloid leukemia - historical
- Acute myeloid leukemia - null regimens
- Acute promyelocytic leukaemia
- Acute promyelocytic leukemia
- Acute promyelocytic leukemia - null regimens
- Acyclovir (Zovirax)
- Adavosertib (MK-1775)
- Adenocarcinoma of unknown primary
- Ado-trastuzumab emtansine (Kadcyla)
- Adrenocortical carcinoma
- Adrenocortical carcinoma - null regimens
- Adult T-cell leukaemia-lymphoma
- Adult T-cell leukemia-lymphoma
- Afatinib (BIBW 2992)
- Afatinib (Gilotrif)
- Afatinib (Gliotrif)
- Aflibercept (Zaltrap)
- Afuresertib
- Afuresertib (GSK2110183)
- Aggressive Non-Hodgkin lymphoma
- Aldesleukin (Proleukin)
- Alectinib (Alecensa)
- Alemtuzumab (Campath)
- Alendronate (Fosamax)
- Alisertib (MLN8237)
- Alitretinoin (Panretin)
- Alizapride (Litican)
- All-trans retinoic acid (ATRA)
- Allogeneic HSCT
- Allogeneic HSCT conditioning regimens
- Allogeneic stem cells
- Allopurinol (Zyloprim)
- Alpelisib (Piqray)
- Alprazolam (Xanax)
- Altretamine (Hexalen)
- Alvocidib (Flavopiridol)
- Amatuximab (MORAb-009)
- Amifostine (Ethyol)
- Aminocaproic acid (Amicar)
- Aminoglutethimide (Cytadren)
- Aminopterin
- Amivantamab (Rybrevant)
- Aml
- Amonafide (Quinamed)
- Amoxicillin
- Ampicillin
- Amrubicin (Calsed)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anakinra (Kineret)
- Anal cancer
- Anal carcinoma
- Anaplastic glioma
- Anaplastic glioma - null regimens
- Anaplastic large cell lymphoma
- Anaplastic large cell lymphoma, pediatric
- Anastrozole (Arimidex)
- Ancestim (Stemgen)
- Andexanet alfa (PRT4445)
- Anemia
- Anti-inhibitor coagulant complex (FEIBA NF)
- Antidepressants
- Antidepressants and other psychiatric medications in cancer care
- Antiemesis
- Antimicrobial prophylaxis
- Antiphospholipid antibody syndrome
- Antithrombin III (Thrombate III)
- Antithrombin III (human and recombinant)
- Antithymocyte globulin, horse ATG (Atgam)
- Antithymocyte globulin, rabbit ATG (Grafalon)
- Antithymocyte globulin, rabbit ATG (Thymoglobulin)
- Apalutamide (ARN-509)
- Apalutamide (Erleada)
- Apatinib (Aitan)
- Apatinib (YN968D1)
- Apixaban (Eliquis)
- Apl
- Aplastic anemia
- Apml
- Aprepitant (Emend)
- Ara-C
- Argatroban
- Argatroban (Acova)
- Aric's Test Page
- Aripiprazole (Abilify)
- Arsenic trioxide (Trisenox)
- Asciminib (ABL001)
- Ascorbic acid (Vitamin C)
- Asparaginase (Elspar)
- Asparaginase Erwinia chrysanthemi (Erwinaze)
- Asparaginase erwinia chrysanthemi-rywn (Rylaze)
- Aspirin
- Aspirin and dipyridamole (Aggrenox)
- Atenolol
- Atezolizumab (MPDL3280A)
- Atezolizumab (Tecentriq)
- Atezolizumab (Tecentriq) for metastatic bladder cancer
- Atezolizumab (Tecentriq) in all diseases
- Atovaquone (Mepron)
- Atropine (Atropen)
- Atypical hemolytic-uremic syndrome
- Atypical hemolytic uremic syndrome
- Atypical hemolytic uremic syndrome (aHUS)
- Autoimmune cytopenia
- Autoimmune cytopenias
- Autoimmune hemolytic anemia
- Autoimmune hemolytic anemia (AIHA)
- Autoimmune thrombocytopenic purpura (ITP)
- Autologous HSCT
- Autologous HSCT conditioning regimens
- Avapritinib (Ayvakit)
- Avatrombopag (Doptelet)
- Avatrombopag (E5501)
- Avelumab (Bavencio)
- Avelumab (Bavencio) for merkel cell carcinoma
- Avelumab (Bavencio) for metastatic bladder cancer
- Avelumab (Bavencio) in all diseases
- Axicabtagene ciloleucel (KTE-C19)
- Axicabtagene ciloleucel (Yescarta)
- Axitinib (Inlyta)
- Aymen's Test Page
- Azacitidine (Onureg)
- Azacitidine (Vidaza)
- Azacitidine oral (Onureg)
- Azathioprine (Imuran)
- B-cell acute lymphoblastic leukaemia
- B-cell acute lymphoblastic leukaemia, Ph-positive
- B-cell acute lymphoblastic leukemia
- B-cell acute lymphoblastic leukemia, Ph-positive
- B-cell acute lymphoblastic leukemia, Ph-positive, pediatric
- B-cell acute lymphoblastic leukemia, pediatric
- B-cell acute lymphoblastic leukemia - historical
- B-cell lymphoma of mucosa-associated lymphoid tissue
- BHQ880
- BHQ880 (Anti-DKK1 Antibody)
- BIDMC clinical trials
- BL22 immunotoxin (CAT-3888)
- BPDCN
- BRAF
- Bacillus Calmette-Guérin (BCG)
- Bacillus Calmette-Guérin (BCG, TheraCys)
- Barasertib (AZD1152)
- Basal cell and squamous cell skin cancer
- Basal cell carcinoma (BCC)
- Basics of Pain Management
- Bavituximab (PGN401)
- Bb2121
- Belagenpumatucel-L (Lucanix)
- Belantamab mafodotin (Blenrep)
- Belinostat (Beleodaq)
- Belotecan (Camptobell)
- Belumosudil (Rezurock)
- Belzutifan (Welireg)
- Bendamustine
- Bendamustine (Bendeka)
- Bendamustine (Treanda)
- Benralizumab (Fasenra)
- Beta thalassemia
- Beth Israel Deaconess Medical Center Hematology Oncology Fellowship
- Betrixaban (Bevyxxa)
- Bevacizumab-awwb (Mvasi)
- Bevacizumab-bvzr (Zirabev)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Billing codes (CPT) and wRVUs
- Binimetinib (MEK162)
- Binimetinib (Mektovi)
- Biomarkers
- Bismuth subcitrate
- Bismuth subsalicylate (Pepto-Bismol)
- Bivalirudin (Angiomax)
- Bladder cancer
- Bladder cancer - historical
- Bladder cancer - null regimens
- Blastic plasmacytoid dendritic cell neoplasm
- Bleeding disorders and risk
- Bleeding with anticoagulation
- Bleomycin (Blenoxane)
- Blinatumomab (AMG 103)
- Blinatumomab (Blincyto)
- Bone cancer
- Bone marrow biopsy procedure instructions and information
- Bone sarcoma
- Bortezomib (Velcade)
- Boston University Medical Center Hematology Oncology Fellowship
- Bosulif
- Bosutinib
- Bosutinib (Bosulif)
- Bosutinib (SKI-606)
- Brachytherapy
- Breast Cancer
- Breast cancer
- Breast cancer, BRCA-mutated
- Breast cancer, ER-positive
- Breast cancer, ER and HER2 co-expressing
- Breast cancer, HER2-positive
- Breast cancer, HER2-positive - historical
- Breast cancer, PIK3CA-mutated
- Breast cancer, triple negative
- Breast cancer - historical
- Breast cancer - null regimens
- Breast cancer BRCA1 & BRCA2 genetic testing
- Brentuximab vedotin (Adcetris)
- Brexucabtagene autoleucel (Tecartus)
- Brigatinib (AP26113)
- Brigatinib (Alunbrig)
- Brigatinib (Alunbrig) for advanced or metastatic ALK-positive non-small cell lung cancer
- Brigatinib (Alunbrig) in all diseases
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute Hematology Oncology Fellowship
- Buparlisib (BKM120)
- Burkitt lymphoma
- Busulfan (Myleran)
- CAL-101
- CAR T-cell toxicity management
- CAT-3888 (BL22)
- CC-292 (AVL-292)
- CLL
- CMML
- CNS carcinoma
- CNS leukaemia
- CNS leukemia
- CNS lymphoma
- CNS lymphoma - null regimens
- CNS melanoma
- COVID-19 and cancer
- COVID-19 coronavirus and cancer
- COVID-19 coronavirus medical center experiences
- COVID-19 coronavirus patient experiences
- CPX-351
- CTCL
- Cabazitaxel (Jevtana)
- Cabozantinib (Cabometyx)
- Cabozantinib (Cometriq)
- Cabozantinib (XL184)
- Calaspargase (Asparlas)
- Calcium phosphate rinse (Caphosol)
- Camrelizumab (AiRuiKa)
- Cancer-related fatigue
- Cangrelor (Kengreal)
- Capecitabine (Xeloda)
- Capivasertib (AZD5363)
- Caplacizumab
- Caplacizumab (ALX-0081)
- Caplacizumab (Cablivi)
- Capmatinib (Tabrecta)
- Carboplatin, Pemetrexed, Pembrolizumab in advanced or metastatic non-small cell lung cancer
- Carboplatin & gemcitabine for unresectable or metastatic bladder cancer
- Carboplatin & gemcitabine in all diseases
- Carboplatin (Paraplatin)
- Carcinoma of unknown primary
- Carfilzomib
- Carfilzomib (Kyprolis)
- Carfilzomib (PR-171)
- Carmustine (BCNU)
- Carmustine (BiCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel)
- Carmustine wafer, polifeprosan 20 (Gliadel wafer)
- Caspofungin (Cancidas)
- Castleman disease
- Castleman’s disease
- Catumaxomab (Removab)
- Cediranib (Recentin)
- Cefixime (Suprax)
- Cemiplimab (Libtayo)
- Cemiplimab (REGN2810)
- Central nervous system (CNS) cancer
- Cephalexin (Keflex)
- Ceritinib (Zykadia)
- Cervical cancer
- Cervical cancer - null regimens
- Cetirizine (Zyrtec)
- Cetuximab (Erbitux)
- Chemotherapy
- Chemotherapy-induced peripheral neuropathy
- Chidamide (Epidaza)
- Chlorambucil (Leukeran)
- Chlorpheniramine (Chlor-Trimeton)
- Cholangiocarcinoma
- Cholangiocarcinoma - null regimens
- Chronic lymphocytic leukaemia (CLL/SLL)
- Chronic lymphocytic leukemia
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Chronic lymphocytic leukemia (CLL/SLL)
- Chronic lymphocytic leukemia - historical
- Chronic myelogenous leukaemia
- Chronic myelogenous leukemia
- Chronic myelogenous leukemia, pediatric
- Chronic myelomonocytic leukaemia
- Chronic myelomonocytic leukemia
- Cilostazol (Pletal)
- Ciltacabtagene autoleucel (JNJ-68284528)
- Cimetidine (Tagamet)
- Ciprofloxacin (Cipro)
- Cisplatin
- Cisplatin & Gemcitabine for bladder cancer, neoadjuvant
- Cisplatin & Gemcitabine in all diseases
- Cisplatin (Platinol)
- Cixutumumab (IMC-A12)